- Oseltamivir Impurity C
-
- $0.00 / 10mg
-
2024-04-10
- CAS:187227-45-8
- Min. Order: 10mg
- Purity: 90%+
- Supply Ability: 10g
|
| | OSELTAMIVIR ACID Basic information |
| Product Name: | OSELTAMIVIR ACID | | Synonyms: | Oseltamivir acid, >=98%;Oseltamivir EP Impurity C;Oseltamivir carboxylate (OC),Metabolite of oseltamivir;(3R,4R,5S)-4-acetamido-5-amino-3-(pentan-3-yloxy)cyclohex-1-enecarboxylic acid;(3R,4R,5S)-4-Acetamido-5-amino-3-(1-ethylpropoxy)-1-cyclohex-ene-1-carboxylic acid;1-Cyclohexene-1-carboxylic acid, 4-(acetylamino)-5-amino-3-(1-ethylpropoxy)-, (3R,4R,5S)-;204255-11-8 (Monophospate salt);Aids095377 | | CAS: | 187227-45-8 | | MF: | C14H24N2O4 | | MW: | 284.35 | | EINECS: | | | Product Categories: | Various Metabolites and Impurities;Metabolites;Amines;Intermediates & Fine Chemicals;Metabolites & Impurities;Pharmaceuticals | | Mol File: | 187227-45-8.mol |  |
| | OSELTAMIVIR ACID Chemical Properties |
| | OSELTAMIVIR ACID Usage And Synthesis |
| Description | Oseltamivir (GS-4104) is an antiviral prodrug targeted against the influenza viruses. Oseltamivir acid is the active metabolite of oseltamivir. It acts as an inhibitor of influenza neuraminidases A and B (IC50 = 0.1 to 4.9 nM for both enzymes), in this way preventing virus budding and release. | | Chemical Properties | White Solid | | Uses | Oseltamivir Acid is a metabolite of Oseltamivir (O701000). | | Uses | Oseltamivir Acid (Oseltamivir EP Impurity C) is a metabolite of Oseltamivir (O701000). It is a COVID19-related research product. | | Definition | ChEBI: A cyclohexenecarboxylic acid that is cyclohex-1-ene-1-carboxylic acid which is substituted at positions 3, 4, and 5 by pentan-3-yloxy, acetamido, and amino groups, respectively (the 3R,4R,5S enantiomer). A
antiviral drug, it is used as the corresponding ethyl ester prodrug, oseltamivir, to slow the spread of influenza. | | references | [1] enguang feng, deju ye, jian li, dengyou zhang, jinfang wang, fei zhao, rolf hilgenfeld, mingyue zheng, hualiang jiang and hong liu. recent advances in neuraminidase inhibitor development as anti-influenza drugs. chem med chem 2012, 7: 1527 – 1536.
[2] tom jefferson reviewer, mark jones, peter doshi, elizabeth a spencer, igho onakpoya, carl j heneghan. oseltamivir for influenza in adults and children: systematic review of clinical study reports and summary of regulatory comment. bmj. 2014, 348: g2545.
[3] rashmi dixit, gulam khandaker, scott ilgoutz, harunor rashid and robert booy. emergence of oseltamivir resistance: control and management of influenza before, during and after the pandemic. infectious disorders – drug targets. 2013, 13 (1): 34-45. |
| | OSELTAMIVIR ACID Preparation Products And Raw materials |
|